SME campus (Part I) | Focus on therapeutics
Speakers:
- Marc Gitzinger – CEO and Founder, BioVersys AG
- Nadine Taudte – Head of Laboratory, Periotrap Pharmaceuticals
This content has been restricted to logged in users only. Please login to view this content.
- Samareh Azeredo da Silveira Lajaunias – Founding Partner and General Manager, Combioxin SA
- Holger Zimmermann, CEO, AiCuris
This content has been restricted to logged in users only. Please login to view this content.
Play Video
This might also be of interest for you:
- More information on Periotrap’s activities can be found here
- Petriotrap’s antimicrobial activity study has been published in April this year showing biofilm inhibition of our developed drug formulation, now the according paper detailing its optimized mechanical and drug release properties is out as well
- News release, 14 July: BIOVERSYS AND PARTNERS FROM LILLE SIGN LONG-TERM COLLABORATION AGREEMENT CREATING A UNIQUE CROSS-BORDER AMR CLUSTER IN ANTIMICROBIAL RESEARCH EXCELLENCE
- News release, 23 June: BIOVERSYS RECEIVES QIDP DESIGNATION FROM THE U.S. FDA FOR THE DEVELOPMENT OF A FIXED COMBINATION OF BVL-GSK098 AND ETH
- News release, AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference
- News release, 4 May: Combioxin SA announces that it has received positive feedback from FDA on its pre- investigational new drug application (PIND) for use of CAL02 in COVID-19 patients at high risk of secondary bacterial infections
- BioVersys AG, Periotrap Pharmaceuticals, AiCuris in the AMR Stakeholder Guide
